These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 8375728

  • 21. The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: real or not?
    Ruggiero A, Rizzo D, Trombatore G, Maurizi P, Riccardi R.
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):19-26. PubMed ID: 26589789
    [Abstract] [Full Text] [Related]

  • 22. Time course of the change and amelioration of nedaplatin-induced nephrotoxicity in rats.
    Uehara T, Tsuchiya N, Masuda A, Torii M, Nakamura M, Yamate J, Maruyama T.
    J Appl Toxicol; 2008 Apr; 28(3):388-98. PubMed ID: 17685399
    [Abstract] [Full Text] [Related]

  • 23. [Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention].
    Montaguti M, Brandolini C, Ferri GG, Hatzopoulos S, Prete A, Pession A.
    Acta Otorhinolaryngol Ital; 2002 Feb; 22(1):14-8. PubMed ID: 12236007
    [Abstract] [Full Text] [Related]

  • 24. A retrospective evaluation of furosemide and mannitol for prevention of cisplatin-induced nephrotoxicity.
    Mach CM, Kha C, Nguyen D, Shumway J, Meaders KM, Ludwig M, Williams-Brown MY, Anderson ML.
    J Clin Pharm Ther; 2017 Jun; 42(3):286-291. PubMed ID: 28276070
    [Abstract] [Full Text] [Related]

  • 25. Modern methods for diagnosis and monitoring of nephrotoxicity during antitumor therapy with platinum derivatives.
    Lyubimova NV, Topchieva SV, Averinova SG, Kashkadaeva AV, Gorbunova VA, Shiryaev SV, Kushlinskii NE.
    Bull Exp Biol Med; 2000 Sep; 130(9):886-91. PubMed ID: 11177273
    [Abstract] [Full Text] [Related]

  • 26. Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity.
    Goren MP, Forastiere AA, Wright RK, Horowitz ME, Dodge RK, Kamen BA, Viar MJ, Pratt CB.
    Cancer Chemother Pharmacol; 1987 Sep; 19(1):57-60. PubMed ID: 2880677
    [Abstract] [Full Text] [Related]

  • 27. [Present status of cisplatin (CDDP) analogues in Japan].
    Majima H.
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1373-8. PubMed ID: 2658825
    [Abstract] [Full Text] [Related]

  • 28. [Experimental evaluation of cisplatin analogous in urogenital cancer].
    Machida T, Akasaka Y.
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1386-92. PubMed ID: 2658827
    [Abstract] [Full Text] [Related]

  • 29. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.
    Ottaiano A, Tambaro R, Greggi S, Prato R, Di Maio M, Esposito G, Scala F, Barletta E, Losito S, De Vivo R, Iaffaioli VR, Pignata S.
    Anticancer Res; 2003 Apr; 23(4):3465-8. PubMed ID: 12926091
    [Abstract] [Full Text] [Related]

  • 30. Platinum dose-intensity.
    Los G.
    J Infus Chemother; 1996 Apr; 6(2):64-8. PubMed ID: 8809651
    [Abstract] [Full Text] [Related]

  • 31. [Can cisplatin renal toxicity be prevented?].
    Brillet G, Deray G, Bunker D, Ben Hmida M, Baumelou A, Jacobs C.
    Nephrologie; 1991 Apr; 12(3):143-6. PubMed ID: 1922654
    [Abstract] [Full Text] [Related]

  • 32. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
    Bonetti A, Apostoli P, Zaninelli M, Pavanel F, Colombatti M, Cetto GL, Franceschi T, Sperotto L, Leone R.
    Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Comparative adverse effect profiles of platinum drugs.
    McKeage MJ.
    Drug Saf; 1995 Oct; 13(4):228-44. PubMed ID: 8573296
    [Abstract] [Full Text] [Related]

  • 36. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers.
    Monk BJ, Alberts DS, Burger RA, Fanta PT, Hallum AV, Hatch KD, Salmon SE.
    Gynecol Oncol; 1998 Nov; 71(2):308-12. PubMed ID: 9826477
    [Abstract] [Full Text] [Related]

  • 37. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.
    Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR.
    Cancer Res; 1984 Apr; 44(4):1693-7. PubMed ID: 6367971
    [Abstract] [Full Text] [Related]

  • 38. [Comparative study of the action of antineoplastic platinum compounds with varying nephrotoxic effects].
    Bakhteeva VT, Fok EM, Lavrova EA.
    Vopr Med Khim; 1996 Apr; 42(4):301-6. PubMed ID: 9254514
    [Abstract] [Full Text] [Related]

  • 39. Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome.
    Beyer J, Rick O, Weinknecht S, Kingreen D, Lenz K, Siegert W.
    Bone Marrow Transplant; 1997 Nov; 20(10):813-9. PubMed ID: 9404920
    [Abstract] [Full Text] [Related]

  • 40. Experimental study of renal disorder caused by oxaliplatin in rat renal cortical slices.
    Kanou T, Uozumi J, Soejima K, Tokuda Y, Masaki Z.
    Clin Exp Nephrol; 2004 Dec; 8(4):310-5. PubMed ID: 15619029
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.